RhumbLine Advisers
CRBU icon

RhumbLine Advisers’s Caribou Biosciences CRBU Stock Holding History

RhumbLine Advisers’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-116,590
Closed -$106K – 4164
2025
Q1 		$106K Sell
116,590
-11,869
-9% -$15.4K ﹤0.01% 3372
2024
Q4 		$204K Buy
128,459
+1,535
+1% +$3.09K ﹤0.01% 3189
2024
Q3 		$249K Buy
126,924
+2,009
+2% +$4.11K ﹤0.01% 3126
2024
Q2 		$205K Buy
124,915
+2,398
+2% +$7.66K ﹤0.01% 3212
2024
Q1 		$630K Buy
122,517
+3,455
+3% +$21.3K ﹤0.01% 2519
2023
Q4 		$682K Buy
119,062
+10,864
+10% +$53.7K ﹤0.01% 2486
2023
Q3 		$517K Buy
108,198
+21,686
+25% +$135K ﹤0.01% 2594
2023
Q2 		$368K Sell
86,512
-961
-1% -$4.32K ﹤0.01% 2883
2023
Q1 		$464K Buy
87,473
+2,255
+3% +$14K ﹤0.01% 2473
2022
Q4 		$535K Buy
85,218
+350
+0.4% +$3.11K ﹤0.01% 2433
2022
Q3 		$895K Buy
84,868
+8,530
+11% +$79.5K ﹤0.01% 2188
2022
Q2 		$415K Buy
76,338
+27,980
+58% +$214K ﹤0.01% 2590
2022
Q1 		$444K Buy
48,358
+28,633
+145% +$302K ﹤0.01% 2477
2021
Q4 		$298K Buy
19,725
+2,126
+12% +$41.3K ﹤0.01% 2706
2021
Q3 		$420K Buy
+17,599
New +$430K ﹤0.01% 2620

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's CRBU Position: Q2 2025 in Review

RhumbLine Advisers sold out of Caribou Biosciences (CRBU) in Q2 2025, closing a stake of 116,590 shares — an estimated $106K sold.

RhumbLine Advisers first reported a position in CRBU in Q3 2021 and held it in 15 quarters. The position peaked at $895K in Q3 2022. 129 funds tracked by Wall St. Rank hold CRBU as of Q2 2025.

  • RhumbLine Advisers reported no remaining Caribou Biosciences position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 116,590 Caribou Biosciences shares in Q2 2025, an estimated $106K.
  • RhumbLine Advisers first reported a position in Caribou Biosciences in Q3 2021 and held it in 15 quarters.
  • RhumbLine Advisers's Caribou Biosciences position peaked at $895K in Q3 2022.
  • 129 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.